# Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026

*Canonical URL: https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026*

## What topics and trends defined most-cited Acute Myeloid Leukemia Research research in the Class of 2026?

AML research in the Class of 2026 is driven by measurable residual disease (MRD) surveillance and venetoclax-azacitidine combination therapies. Topic evolution shows a dramatic 5-fold surge in KMT2A rearrangement and Menin inhibitor studies, while general single-cell transcriptomics and isolated baseline gene mutation analyses showed relative declines.

## At a glance

| Fact | Value |
| --- | --- |
| Field | Acute Myeloid Leukemia Research |
| Cohort label | Class of 2026 (2024 publications) |
| Papers analyzed | 6,270 |
| Papers ranked | 20 |
| Top topics in ranked papers | Measurable residual disease (MRD), Venetoclax, KMT2A rearrangement, Azacitidine, Menin inhibitor |
| Publication window | Jan 1, 2024 – Dec 31, 2024 |
| Eligibility | Research articles; reviews excluded |
| Citation window | 18 months post-publication |
| 18m citation range | 36–147 |
| Data source | OpenAlex · Retrieved Jul 2026 |
| License | CC BY 4.0 |

## Rankings

| Rank | Title | Authors | Corresponding authors | Affiliation | Journal | 18m citations | DOI |
| ---: | --- | --- | --- | --- | --- | ---: | --- |
| 1 | Genetic risk classification for adults with AML receiving less-intensive therapies: the 2024 ELN recommendations | Hartmut Döhner, Courtney D DiNardo, Frederick R Appelbaum, Charles Craddock, Hervé Dombret, Benjamin L Ebert, Pierre Fenaux, Lucy A Godley, Robert P Hasserjian, Richard A Larson, Ross L Levine, Yasushi Miyazaki, Dietger Niederwieser, Gert Ossenkoppele, Christoph Röllig, Jorge Sierra, Eytan M Stein, Martin S Tallman, Hwei-Fang Tien, Jianxiang Wang, Agnieszka Wierzbowska, Andrew H Wei, Bob Löwenberg | Hartmut Döhner | Ulm University Hospital, Germany | Blood | 147 | 10.1182/blood.2024025409 |
| 2 | Menin Inhibition With Revumenib for <i>KMT2A</i> -Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101) | Ghayas C Issa, Ibrahim Aldoss, Michael J Thirman, John DiPersio, Martha Arellano, James S Blachly, Gabriel N Mannis, Alexander Perl, David S Dickens, Christine M McMahon, Elie Traer, C Michel Zwaan, Carolyn S Grove, Richard Stone, Paul J Shami, Ioannis Mantzaris, Matthew Greenwood, Neerav Shukla, Branko Cuglievan, Tibor Kovacsovics, Yu Gu, Rebecca G Bagley, Kate Madigan, Yakov Chudnovsky, Huy Van Nguyen, Nicole McNeer, Eytan M Stein | Ghayas C Issa | The University of Texas MD Anderson Cancer Center, United States | Journal of Clinical Oncology | 136 | 10.1200/jco.24.00826 |
| 3 | Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of <i>FLT3</i> | Mark J Levis, Mehdi Hamadani, Brent Logan, Richard J Jones, Anurag K Singh, Mark Litzow, John R Wingard, Esperanza B Papadopoulos, Alexander E Perl, Robert J Soiffer, Celalettin Ustun, Masumi Ueda Oshima, Geoffrey L Uy, Edmund K Waller, Sumithra Vasu, Melhem Solh, Asmita Mishra, Lori Muffly, Hee-Je Kim, Jan-Henrik Mikesch, Yuho Najima, Masahiro Onozawa, Kirsty Thomson, Arnon Nagler, Andrew H Wei, Guido Marcucci, Nancy L Geller, Nahla Hasabou, David Delgado, Matt Rosales, Jason Hill, Stanley C Gill, Rishita Nuthethi, Denise King, Heather Wittsack, Adam Mendizabal, Steven M Devine, Mary M Horowitz, Yi-Bin Chen, BMT-CTN 1506/MORPHO Study Investigators | Mark J Levis | Johns Hopkins University, United States | Journal of Clinical Oncology | 120 | 10.1200/jco.23.02474 |
| 4 | Long‐term follow‐up of <scp>VIALE‐A</scp>: Venetoclax and azacitidine in chemotherapy‐ineligible untreated acute myeloid leukemia | Keith W Pratz, Brian A Jonas, Vinod Pullarkat, Michael J Thirman, Jacqueline S Garcia, Hartmut Döhner, Christian Récher, Walter Fiedler, Kazuhito Yamamoto, Jianxiang Wang, Sung-Soo Yoon, Ofir Wolach, Su-Peng Yeh, Brian Leber, Jordi Esteve, Jiri Mayer, Kimmo Porkka, Árpád Illés, Roberto M Lemoli, Mehmet Turgut, Grace Ku, Catherine Miller, Ying Zhou, Meng Zhang, Brenda Chyla, Jalaja Potluri, Courtney D DiNardo | Keith W. Pratz | University of Pennsylvania, United States | American Journal of Hematology | 114 | 10.1002/ajh.27246 |
| 5 | Genetic risk stratification and outcomes among treatment-naive patients with AML treated with venetoclax and azacitidine | Hartmut Döhner, Keith W Pratz, Courtney D DiNardo, Andrew H Wei, Brian A Jonas, Vinod A Pullarkat, Michael J Thirman, Christian Récher, Andre C Schuh, Sunil Babu, Xiaotong Li, Grace Ku, Zihuan Liu, Yan Sun, Jalaja Potluri, Monique Dail, Brenda Chyla, Daniel A Pollyea | Hartmut Döhner | Ulm University Hospital, Germany | Blood | 104 | 10.1182/blood.2024024944 |
| 6 | Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): a multicentre, open-label, multi-cohort, phase 1 trial | Eunice S Wang, Ghayas C Issa, Harry P Erba, Jessica K Altman, Pau Montesinos, Stephane DeBotton, Roland B Walter, Kristen Pettit, Michael R Savona, Mithun Vinod Shah, Marina Kremyanskaya, Maria R Baer, James M Foran, Gary Schiller, Lionel Adès, Mael Heiblig, Celine Berthon, Pierre Peterlin, Eduardo Rodríguez-Arbolí, Olga Salamero, Mrinal M Patnaik, Cristina Papayannidis, Jolanta Grembecka, Tomasz Cierpicki, Bradley Clegg, Joshua Ray, Brian M Linhares, Kun Nie, Amitava Mitra, Julie Mackey Ahsan, Marilyn Tabachri, Harris S Soifer, Daniel Corum, Mollie Leoni, Stephen Dale, Amir T Fathi | Eunice S. Wang | Roswell Park Comprehensive Cancer Center, United States | The Lancet Oncology | 80 | 10.1016/s1470-2045(24)00386-3 |
| 7 | RAS-mutant leukaemia stem cells drive clinical resistance to venetoclax | Junya Sango, Saul Carcamo, Maria Sirenko, Abhishek Maiti, Hager Mansour, Gulay Ulukaya, Lewis E Tomalin, Nataly Cruz-Rodriguez, Tiansu Wang, Malgorzata Olszewska, Emmanuel Olivier, Manon Jaud, Bettina Nadorp, Benjamin Kroger, Feng Hu, Lewis Silverman, Stephen S Chung, Elvin Wagenblast, Ronan Chaligne, Ann-Kathrin Eisfeld, Deniz Demircioglu, Dan A Landau, Piro Lito, Elli Papaemmanuil, Courtney D DiNardo, Dan Hasson, Marina Konopleva, Eirini P Papapetrou | Eirini P. Papapetrou | Icahn School of Medicine at Mount Sinai, United States | Nature | 76 | 10.1038/s41586-024-08137-x |
| 8 | Global, regional, and national burden of acute myeloid leukemia, 1990–2021: a systematic analysis for the global burden of disease study 2021 | Yeming Zhou, Guiqin Huang, Xiaoya Cai, Ying Liu, Bingxin Qian, Dengju Li | Dengju Li | Huazhong University of Science and Technology, China | Biomarker Research | 75 | 10.1186/s40364-024-00649-y |
| 9 | Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML | Nicholas J Short, Naval Daver, Courtney D Dinardo, Tapan Kadia, Lewis F Nasr, Walid Macaron, Musa Yilmaz, Gautam Borthakur, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Ghayas C Issa, Kelly S Chien, Elias Jabbour, Cedric Nasnas, Xuelin Huang, Wei Qiao, Jairo Matthews, Christopher J Stojanik, Keyur P Patel, Regina Abramova, Jennifer Thankachan, Marina Konopleva, Hagop Kantarjian, Farhad Ravandi | Nicholas J Short | The University of Texas MD Anderson Cancer Center, United States | Journal of Clinical Oncology | 74 | 10.1200/jco.23.01911 |
| 10 | Analysis of somatic mutations in whole blood from 200,618 individuals identifies pervasive positive selection and novel drivers of clonal hematopoiesis | Nicholas Bernstein, Michael Spencer Chapman, Kudzai Nyamondo, Zhenghao Chen, Nicholas Williams, Emily Mitchell, Peter J Campbell, Robert L Cohen, Jyoti Nangalia | Robert L. Cohen, Jyoti Nangalia | Calico Life Sciences LLC, United States | Nature Genetics | 59 | 10.1038/s41588-024-01755-1 |
| 11 | Adult skull bone marrow is an expanding and resilient haematopoietic reservoir | Bong Ihn Koh, Vishal Mohanakrishnan, Hyun-Woo Jeong, Hongryeol Park, Kai Kruse, Young Jun Choi, Melina Nieminen-Kelhä, Rahul Kumar, Raquel S Pereira, Susanne Adams, Hyuek Jong Lee, M Gabriele Bixel, Peter Vajkoczy, Daniela S Krause, Ralf H Adams | Bong Ihn Koh, Ralf H. Adams | Max Planck Institute for Molecular Biomedicine, Germany | Nature | 58 | 10.1038/s41586-024-08163-9 |
| 12 | Molecular, clinical, and therapeutic determinants of outcome in <i>NPM1</i>-mutated AML | Jad Othman, Nicola Potter, Adam Ivey, Yanis Tazi, Elli Papaemmanuil, Jelena Jovanovic, Sylvie D Freeman, Amanda Gilkes, Rosemary Gale, Tanya Rapoz-D'Silva, Manohursingh Runglall, Michelle Kleeman, Pawan Dhami, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Brian Huntly, Nigel H Russell, Richard Dillon | Richard Dillon | King's College London, United Kingdom | Blood | 53 | 10.1182/blood.2024024310 |
| 13 | A new genomic framework to categorize pediatric acute myeloid leukemia | Masayuki Umeda, Jing Ma, Tamara Westover, Yonghui Ni, Guangchun Song, Jamie L Maciaszek, Michael Rusch, Delaram Rahbarinia, Scott Foy, Benjamin J Huang, Michael P Walsh, Priyadarshini Kumar, Yanling Liu, Wenjian Yang, Yiping Fan, Gang Wu, Sharyn D Baker, Xiaotu Ma, Lu Wang, Todd A Alonzo, Jeffrey E Rubnitz, Stanley Pounds, Jeffery M Klco | Jeffery M. Klco | St. Jude Children's Research Hospital, United States | Nature Genetics | 50 | 10.1038/s41588-023-01640-3 |
| 14 | Postinduction molecular MRD identifies patients with <i>NPM1</i> AML who benefit from allogeneic transplant in first remission | Jad Othman, Nicola Potter, Adam Ivey, Jelena Jovanovic, Manohursingh Runglall, Sylvie D Freeman, Amanda Gilkes, Ian Thomas, Sean Johnson, Joanna Canham, Jamie Cavenagh, Panagiotis Kottaridis, Claire Arnold, Hans Beier Ommen, Ulrik Malthe Overgaard, Mike Dennis, Alan Burnett, Charlotte Wilhelm-Benartzi, Richard Dillon, Nigel H Russell | Jad Othman | King's College London, United Kingdom | Blood | 46 | 10.1182/blood.2023023096 |
| 15 | Preclinical efficacy of the potent, selective menin-KMT2A inhibitor JNJ-75276617 (bleximenib) in <i>KMT2A</i>- and <i>NPM1</i>-altered leukemias | Min Chul Kwon, Jan Willem Thuring, Olivier Querolle, Xuedong Dai, Tinne Verhulst, Vineet Pande, Ann Marien, Dries Goffin, Daniela V Wenge, Hong Yue, Jevon A Cutler, Cyrus Jin, Florian Perner, Shanna M Hogeling, Paul L Shaffer, Frank Jacobs, Petra Vinken, Wei Cai, Vikki Keersmaekers, Filmon Eyassu, Balpreet Bhogal, Karin Verstraeten, Sara El Ashkar, Jennifer A Perry, Prathiba Jayaguru, Laura Barreyro, Anna Kuchnio, Nicolas Darville, Daniel Krosky, Gregor Urbanietz, Bie Verbist, James P Edwards, Glenn S Cowley, Robert Kirkpatrick, Ruth Steele, Lucille Ferrante, Christina Guttke, Nikki Daskalakis, E Christine Pietsch, David M Wilson, Ricardo Attar, Yusri Elsayed, Eric S Fischer, Jan Jacob Schuringa, Scott A Armstrong, Kathryn Packman, Ulrike Philippar | Min Chul Kwon | Janssen R&D, Belgium | Blood | 40 | 10.1182/blood.2023022480 |
| 16 | Single-cell transcriptomes identify patient-tailored therapies for selective co-inhibition of cancer clones | Aleksandr Ianevski, Kristen Nader, Kyriaki Driva, Wojciech Senkowski, Daria Bulanova, Lidia Moyano-Galceran, Tanja Ruokoranta, Heikki Kuusanmäki, Nemo Ikonen, Philipp Sergeev, Markus Vähä-Koskela, Anil K Giri, Anna Vähärautio, Mika Kontro, Kimmo Porkka, Esa Pitkänen, Caroline A Heckman, Krister Wennerberg, Tero Aittokallio | Tero Aittokallio | University of Helsinki, Finland | Nature Communications | 40 | 10.1038/s41467-024-52980-5 |
| 17 | Comprehensive characterization of IFNγ signaling in acute myeloid leukemia reveals prognostic and therapeutic strategies | Bofei Wang, Patrick K Reville, Mhd Yousuf Yassouf, Fatima Z Jelloul, Christopher Ly, Poonam N Desai, Zhe Wang, Pamella Borges, Ivo Veletic, Enes Dasdemir, Jared K Burks, Guilin Tang, Shengnan Guo, Araceli Isabella Garza, Cedric Nasnas, Nicole R Vaughn, Natalia Baran, Qing Deng, Jairo Matthews, Preethi H Gunaratne, Dinler A Antunes, Suhendan Ekmekcioglu, Koji Sasaki, Miriam B Garcia, Branko Cuglievan, Dapeng Hao, Naval Daver, Michael R Green, Marina Konopleva, Andrew Futreal, Sean M Post, Hussein A Abbas | Hussein A. Abbas | The University of Texas MD Anderson Cancer Center, United States | Nature Communications | 37 | 10.1038/s41467-024-45916-6 |
| 18 | Measurable Residual <i>FLT3</i> Internal Tandem Duplication Before Allogeneic Transplant for Acute Myeloid Leukemia | Laura W Dillon, Gege Gui, Niveditha Ravindra, Georgia Andrew, Devdeep Mukherjee, Zoë C Wong, Ying Huang, Jason Gerhold, Matt Holman, Julian D'Angelo, Jeffrey Miller, Jake Higgins, Jesse J Salk, Jeffery J Auletta, Firas El Chaer, Steven M Devine, Antonio Martin Jimenez-Jimenez, Marcos J G De Lima, Mark R Litzow, Partow Kebriaei, Wael Saber, Stephen R Spellman, Scott L Zeger, Kristin M Page, Christopher S Hourigan | Christopher S. Hourigan | National Institutes of Health, United States | JAMA Oncology | 37 | 10.1001/jamaoncol.2024.0985 |
| 19 | Mimicking clinical trials with synthetic acute myeloid leukemia patients using generative artificial intelligence | Jan-Niklas Eckardt, Waldemar Hahn, Christoph Röllig, Sebastian Stasik, Uwe Platzbecker, Carsten Müller-Tidow, Hubert Serve, Claudia D Baldus, Christoph Schliemann, Kerstin Schäfer-Eckart, Maher Hanoun, Martin Kaufmann, Andreas Burchert, Christian Thiede, Johannes Schetelig, Martin Sedlmayr, Martin Bornhäuser, Markus Wolfien, Jan Moritz Middeke | Jan‐Niklas Eckardt | Technical University Dresden, Germany | npj Digital Medicine | 36 | 10.1038/s41746-024-01076-x |
| 20 | Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial | Matthias Stelljes, Jan Moritz Middeke, Gesine Bug, Eva-Maria Wagner-Drouet, Lutz P Müller, Christoph Schmid, Stefan W Krause, Wolfgang Bethge, Edgar Jost, Uwe Platzbecker, Stefan A Klein, Jörg Schubert, Judith Niederland, Martin Kaufmann, Kerstin Schäfer-Eckart, Markus Schaich, Henning Baldauf, Friedrich Stölzel, Cathleen Petzold, Christoph Röllig, Nael Alakel, Björn Steffen, Beate Hauptrock, Christoph Schliemann, Katja Sockel, Fabian Lang, Oliver Kriege, Judith Schaffrath, Christian Reicherts, Wolfgang E Berdel, Hubert Serve, Gerhard Ehninger, Alexander H Schmidt, Martin Bornhäuser, Jan-Henrik Mikesch, Johannes Schetelig, Study Alliance Leukemia and the German Cooperative Transplant Study Group | Johannes Schetelig, Johannes Schetelig | University Hospital Münster, Germany | The Lancet Haematology | 36 | 10.1016/s2352-3026(24)00065-6 |

## Topic trends

### What Topics Define the Class of 2026?

The 2026 cohort of high-impact acute myeloid leukemia (AML) research is anchored by minimal residual disease (MRD) tracking and combination targeted therapy regimens. Measurable residual disease (MRD) monitoring stands out as the single most prevalent informative focus (24% paper frequency, 12 mentions), underscoring a field-wide transition toward precise molecular response criteria and ultra-sensitive relapse risk stratification post-remission. In parallel, BCL-2 inhibitor venetoclax remains a therapeutic centerpiece (24% paper frequency), frequently investigated alongside hypomethylating agents like azacitidine (12% frequency) to optimize low-intensity frontline protocols and overcome clonal resistance. Genomic driver research continues to emphasize FLT3 internal tandem duplication (FLT3-ITD, 12% frequency) and NPM1 mutations, alongside rising interest in KMT2A rearrangements (10% frequency) and novel Menin inhibitors (8% frequency). Therapeutic evaluation heavily relies on leukemia stem cell (LSC) targeting and patient-derived xenograft (PDX) models (8% frequency each) to decipher chemoresistance mechanisms. Collectively, these focal points reflect a paradigm shift in AML oncology away from uniform intensive chemotherapy toward biomarker-driven, low-toxicity regimens that combine epigenetic priming, targeted apoptotic activation, and rigorous longitudinal MRD surveillance.

*Leading research themes*

### How Did Topics Shift from the Class of 2025 to the Class of 2026?

Comparing top-ranked publications across consecutive cohorts reveals a decisive pivot toward targeted epigenetic reader inhibition and refined molecular subclassifications. The most pronounced expansion occurred in KMT2A rearrangement studies, which surged 5.0-fold from 2% in the Class of 2025 to 10% in the Class of 2026 (5 mentions). This surge closely mirrors the rise of Menin inhibitors (doubling to 8% frequency) and Menin-KMT2A interaction mechanisms, signaling rapid clinical translation of novel targeted therapeutics for genetically defined AML subsets. Secondary FLT3-targeted investigations also gained momentum, with FLT3-internal tandem duplication studies expanding 3.0-fold (to 6% frequency) and gilteritinib evaluation rising 50%. Conversely, exploratory broad-profiling methodologies experienced a relative decline; single-cell RNA sequencing fell from 10% to 6% frequency (-40%), and foundational mutation studies focusing solely on DNMT3A and ASXL1 both decreased by 50% (from 8% to 4%). Similarly, traditional static risk models like the European LeukemiaNet (ELN) classification saw reduced relative prominence (-33%). Overall, topic evolution highlights an accelerating transition from generalized genomics toward mechanism-driven, target-specific interventions tailored to high-risk leukemic drivers.

*How topics shifted year over year*

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Acute Myeloid Leukemia Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/acute-myeloid-leukemia-research/2026. Accessed 2026-07-31.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```